The Role of Checkpoint Inhibitors in Glioblastoma
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00655-3
Abstract: Given its poor prognosis, glioblastoma represents an area of high unmet clinical need. Standard of care for the treatment of glioblastoma in the frontline setting is limited to surgical resection, radiation, and temozolomide, with the… read more here.
Keywords: checkpoint inhibitors; role checkpoint; inhibitors glioblastoma; role ... See more keywords
Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide Potentiation.
Sign Up to like & getrecommendations! Published in 2021 at "ACS chemical neuroscience"
DOI: 10.1021/acschemneuro.1c00494
Abstract: A number of studies have shown high levels of thymidine phosphorylase (TP) expression in glioblastoma (GBM), with trace or undetectable TP levels in normal developed brain tissue. TP catalyzes the reversible phosphorolysis of thymidine to… read more here.
Keywords: thymidine phosphorylase; thymidine; inhibitors glioblastoma; evaluation thymidine ... See more keywords
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Sign Up to like & getrecommendations! Published in 2022 at "Arquivos de Neuro-Psiquiatria"
DOI: 10.1590/0004-282x-anp-2022-s129
Abstract: ABSTRACT Background: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but their role in glioblastoma is uncertain.… read more here.
Keywords: glioblastoma; checkpoint inhibitors; immune checkpoint; glioblastoma learned ... See more keywords
Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.939570
Abstract: Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment. The current treatment for glioblastoma… read more here.
Keywords: parp; development; glioblastoma multiform; parp inhibitors ... See more keywords